Advertisement


Michael A. Thompson, MD, PhD, on Smoldering Multiple Myeloma: Reassessing Risk Stratification Models

2019 ASCO Annual Meeting

Advertisement

Michael A. Thompson, MD, PhD, of Advocate Aurora Health, discusses the implications of the revised diagnostic criteria for multiple myeloma, which removed patients at the highest risk of disease progression from the smoldering group, and a new model for smoldering disease that incorporates revised cutoffs for the previously used parameters (Abstract 8000).



Related Videos

Issues in Oncology
Health-Care Policy

Amy J. Davidoff, PhD, on Racial Disparities in Time to Cancer Treatment: The Effect of Medicaid Expansion

Amy J. Davidoff, PhD, of Yale University School of Public Health, discusses study findings on how expanding access to Medicaid through the Affordable Care Act (ACA) reduced racial disparities among patients with advanced cancer. Before the ACA was implemented in 2014, black patients with cancer were less likely than white patients to receive timely treatment, but in states that did not adopt Medicaid expansion, racial disparities persist (Abstract LBA1).

Leukemia

Mark J. Levis, MD, PhD, on Acute Myeloid Leukemia: Gilteritinib in FLT3-Mutated Disease

Mark J. Levis, MD, PhD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, discusses the effect of gilteritinib on survival in patients with FLT3-mutated relapsed/refractory AML who have common co-mutations or a high FLT3-ITD allelic ratio, and the importance of FLT3-ITD testing at diagnosis and again at relapse (Abstract 7000).

Sarcoma
Immunotherapy

William D. Tap, MD, on Soft-Tissue Sarcomas: ANNOUNCE Trial on Doxorubicin and Olaratumab

William D. Tap, MD, of Memorial Sloan Kettering Cancer Center, discusses negative study findings on doxorubicin plus olaratumab vs doxorubicin plus placebo, which showed no difference in overall survival between the two treatments in patients with advanced soft-tissue sarcomas. The manufacturer is currently withdrawing olaratumab from the global market (Abstract LBA3).

 

Head and Neck Cancer
Immunotherapy

Danny Rischin, MD, on Head and Neck Squamous Cell Carcinoma: KEYNOTE-048 Trial on Pembrolizumab

Danny Rischin, MD, of Peter MacCallum Cancer Centre, discusses phase III results that support pembrolizumab with and without platinum-based chemotherapy plus fluorouracil as new first-line standards of care for recurrent or metastatic head and neck squamous cell carcinoma (Abstract 6000).

Kidney Cancer

Neeraj Agarwal, MD, and Arnaud Méjean, MD, PhD, on Renal Cancer: Cytoreductive Nephrectomy Followed by Sunitinib in the Metastatic Setting

Neeraj Agarwal, MD, of the Huntsman Cancer Institute, and Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges-Pompidou, Paris Descartes University, discuss an update to the CARMENA trial with new phase III study results on the benefit of cytoreductive nephrectomy followed by sunitinib vs sunitinib alone in metastatic renal cell carcinoma (Abstract 4508).

Advertisement

Advertisement




Advertisement